BMC Public Health
(Accessed 27 June 2020)
Development of a TB vaccine trial site in Africa and lessons from the Ebola experience
There is a dire need for a more efficacious TB vaccine. To deploy such vaccines, trials are needed in sites that combine high disease incidence and research infrastructure. We describe our twelve-year experience building a TB vaccine trial site in contrast to the process in the recent Ebola outbreak. There are additional differences. Relative to the Ebola pipeline, TB vaccines have fewer trials and a paucity of government and industry led trials. While pathogens have varying levels of difficulty in the development of new vaccine candidates, there yet appears to be greater interest in funding and coordinating Ebola interventions. TB is a global threat that requires similar concerted effort for elimination.
Authors: G. Kaguthi, V. Nduba, P. Rabuogi, D. Okelloh, S. G. Ouma, G. Blatner, S. Gelderbloem, Ellen M. H. Mitchell, Cherise P. Scott, S. Verver, T. Hawkridge, J. E. M. de Steenwinkel, K. F. Laserson and J. H. Richardus
Citation: BMC Public Health 2020 20:999
Content type: Research in practice
Published on: 26 June 2020